Arabilin overcomes resistance to AR-targeted therapy

被引：3
|
作者：
Fujimaki, Takahiro [1 ]
Saito, Shun [1 ]
Imoto, Masaya [1 ]
机构：
[1] Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Yokohama, Kanagawa, Japan
来源：
JOURNAL OF ANTIBIOTICS | 2017年 / 70卷 / 03期
基金：
日本学术振兴会;
关键词：
ANDROGEN RECEPTOR; PROSTATE-CANCER; ANTIANDROGEN; ANTAGONIST;
D O I：
10.1038/ja.2016.162
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：328 / 330
页数：3
相关论文
共 50 条
  • [1] Arabilin overcomes resistance to AR-targeted therapy
    Takahiro Fujimaki
    Shun Saito
    Masaya Imoto
    The Journal of Antibiotics, 2017, 70 : 328 - 330
  • [2] Antarlides: A New Type of Androgen Receptor (AR) Antagonist that Overcomes Resistance to AR-Targeted Therapy
    Saito, Shun.
    Fujimaki, Takahiro
    Panbangred, Watanalai
    Igarashi, Yasuhiro
    Imoto, Masaya
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2016, 55 (08) : 2728 - 2732
  • [3] Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy
    Geng, Hao
    Xue, Changhui
    Mendonca, Janet
    Sun, Xiao-Xin
    Liu, Qiong
    Reardon, Patrick N.
    Chen, Yingxiao
    Qian, Kendrick
    Hua, Vivian
    Chen, Alice
    Pan, Freddy
    Yuan, Julia
    Dang, Sang
    Beer, Tomasz M.
    Dai, Mu-Shui
    Kachhap, Sushant K.
    Qian, David Z.
    NATURE COMMUNICATIONS, 2018, 9
  • [4] Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy
    Hao Geng
    Changhui Xue
    Janet Mendonca
    Xiao-Xin Sun
    Qiong Liu
    Patrick N. Reardon
    Yingxiao Chen
    Kendrick Qian
    Vivian Hua
    Alice Chen
    Freddy Pan
    Julia Yuan
    Sang Dang
    Tomasz M. Beer
    Mu-Shui Dai
    Sushant K. Kachhap
    David Z. Qian
    Nature Communications, 9
  • [5] Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation
    Zhang, Zeda
    Zhou, Chuanli
    Li, Xiaoling
    Barnes, Spencer D.
    Deng, Su
    Hoover, Elizabeth
    Chen, Chi-Chao
    Lee, Young Sun
    Zhang, Yanxiao
    Wang, Choushi
    Metang, Lauren A.
    Wu, Chao
    Tirado, Carla Rodriguez
    Johnson, Nickolas A.
    Wongvipat, John
    Navrazhina, Kristina
    Cao, Zhen
    Choi, Danielle
    Huang, Chun-Hao
    Linton, Eliot
    Chen, Xiaoping
    Liang, Yupu
    Mason, Christopher E.
    de Stanchina, Elisa
    Abida, Wassim
    Lujambio, Amaia
    Li, Sheng
    Lowe, Scott W.
    Mendell, Joshua T.
    Malladi, Venkat S.
    Sawyers, Charles L.
    Mu, Ping
    CANCER CELL, 2020, 37 (04) : 584 - +
  • [6] Targeting resistance mechanisms to AR-targeted therapy in prostate cancer through inhibition of CREBBP/EP300
    Dougherty, Bonnie V.
    Thomas, Beatrice C.
    Walsh, Alice M.
    Calvo, Veronica
    Ware, Kathryne E.
    Armstrong, Andrew J.
    Renstrup, Jens
    Somarelli, Jason A.
    Schadt, Eric E.
    CANCER RESEARCH, 2024, 84 (06)
  • [7] The role of SOX2 in promoting resistance to AR-targeted therapies in prostate cancer
    de Wet, Larischa
    Williams, Anthony
    Gillard, Marc
    Kregel, Steve
    Garcia, Tzintzuni
    McAuley, Erin
    Brown, Ryan
    Vander Griend, Donald
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer
    Li, Xiaoling
    Wang, Yunguan
    Deng, Su
    Zhu, Guanghui
    Wang, Choushi
    Johnson, Nickolas A.
    Zhang, Zeda
    Tirado, Carla Rodriguez
    Xu, Yaru
    Metang, Lauren A.
    Gonzalez, Julisa
    Mukherji, Atreyi
    Ye, Jianfeng
    Yang, Yuqiu
    Peng, Wei
    Tang, Yitao
    Hofstad, Mia
    Xie, Zhiqun
    Yoon, Heewon
    Chen, Liping
    Liu, Xihui
    Chen, Sujun
    Zhu, Hong
    Strand, Douglas
    Liang, Han
    Raj, Ganesh
    He, Housheng Hansen
    Mendell, Joshua T.
    Li, Bo
    Wang, Tao
    Mu, Ping
    CANCER CELL, 2023, 41 (08) : 1427 - +
  • [9] Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy
    Hao Geng
    Changhui Xue
    Janet Mendonca
    Xiao-Xin Sun
    Qiong Liu
    Patrick N. Reardon
    Yingxiao Chen
    Kendrick Qian
    Vivian Hua
    Alice Chen
    Freddy Pan
    Julia Yuan
    Sang Dang
    Tomasz M. Beer
    Mu-Shui Dai
    Sushant K. Kachhap
    David Z. Qian
    Nature Communications, 10
  • [10] Sequencing AR-targeted agents might be ineffective in mCRPC
    Heidenreich, Axel
    Pfister, David
    NATURE REVIEWS UROLOGY, 2015, 12 (05) : 246 - 247
12345